Merck KGaA to flog Allergopharma business to Dermapharm

pharmafile | February 21, 2020 | News story | Medical Communications, Sales and Marketing Allergopharma, Dermapharm, Merck KGaA, pharma 

German-based drugmaker Merck KGaA has confirmed its intention to divest its allergy business Allergopharma to Dermapharm, another German manufacturer of generics, dietary products, cosmetics and medical devices.

The business unit generated €88 million for Merck in 2018. It is currently developing a competitor to Mylan’s flagship EpiPen epinephrine autoinjector as a treatment for anaphylactic reactions.

The agreement includes Allergopharma’s therapeutic and diagnostic portfolio, but also its production site located in Reinbek, Germany.

The value of the sale was not disclosed, but Merck’s share price rose 1.34% on announcement of the news, while Dermapharm’s rose by 3.05%.

It was confirmed that the deal is expected to close in the second quarter of this year, subject to regulatory approval and satisfaction of closing conditions.

Matt Fellows

Related Content

Pfizer sign

Delayed Pfizer vaccine dose gives 3.5 times more immunity, study shows

The Pfizer-BioNTech COVID-19 vaccine is around three and a half times more effective when dosed …

Amgen flag

AstraZeneca and Amgen asthma drug shows positive results in Phase III trial

AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority …

India report record number of COVID deaths as bodies drift down Ganges

India yesterday reported the country’s highest COVID-19 death total for a single day, with 4,205 …

Latest content